新抗癌药——米托蒽醌

来源 :新药与临床 | 被引量 : 0次 | 上传用户:binga2009
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
米托蒽醌(mitoxantrone,MA)是一种蒽醌抗肿瘤药,其结构与阿霉素相似,但其母体分子C~9上无氨基葡萄糖部分(图1)。 图1.米托蒽醌结构式 药理学和药物动力学 MA的机理未明。可认作非特异性细胞周期药,因它可杀灭任何细胞周期的癌细胞,增殖与非增殖细胞均受抑制;但对分裂期细胞比休止期细胞更敏感。对细胞周期“S”后期最为敏感。 Mitoxantrone (MA) is an anthraquinone antineoplastic agent that has a similar structure to doxorubicin but does not contain any glucosamine moiety on its parent molecule C-9 (Figure 1). Figure 1. Mitoxantrone structural pharmacology and pharmacokinetics MA mechanism is unknown. Can be considered as non-specific cell cycle drugs, because it can kill any cell cycle of cancer cells, proliferation and non-proliferating cells are inhibited; but dividing cells are more sensitive than resting cells. Most sensitive to the late “S” cell cycle.
其他文献